Newron Pharmaceuticals (Switzerland) Insiders
| NWRN Stock | CHF 8.10 0.22 2.64% |
Newron Pharmaceuticals employs about 25 people. The company is managed by 4 executives with a total tenure of roughly 59 years, averaging almost 14.0 years of service per executive, having 6.25 employees per reported executive. Recap of Newron Pharmaceuticals' management performance can provide insight into the venture performance.
| Ravi Anand Insider Chief Officer |
| Roberto Galli Insider VP Fin |
Newron |
Newron Pharmaceuticals Management Team Effectiveness
The company has return on total asset (ROA) of (0.1636) % which means that it has lost $0.1636 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (8.398) %, meaning that it generated substantial loss on money invested by shareholders. Newron Pharmaceuticals' management efficiency ratios could be used to measure how well Newron Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.Newron Pharmaceuticals Workforce Comparison
Newron Pharmaceuticals SpA is rated below average in number of employees category among its peers. The total workforce of Biotechnology industry is now estimated at about 621. Newron Pharmaceuticals holds roughly 25.0 in number of employees claiming about 4% of stocks in Biotechnology industry.
The company has Profit Margin (PM) of (2.44) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (1.84) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $1.84. Newron Pharmaceuticals Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. Newron Pharmaceuticals Price Series Summation is a cross summation of Newron Pharmaceuticals price series and its benchmark/peer.
Newron Pharmaceuticals Notable Stakeholders
A Newron Pharmaceuticals stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Newron Pharmaceuticals often face trade-offs trying to please all of them. Newron Pharmaceuticals' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Newron Pharmaceuticals' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Ravi Anand | Chief Officer | Profile | |
| Roberto Galli | VP Fin | Profile | |
| Stefan Weber | CEO Director | Profile | |
| Marco Caremi | Exec Devel | Profile |
About Newron Pharmaceuticals Management Performance
The success or failure of an entity such as Newron Pharmaceuticals often depends on how effective the management is. Newron Pharmaceuticals management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Newron management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Newron management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Newron Pharmaceuticals S.p.A., a clinical stage biopharmaceutical company, focuses on the research and development, manufacture, and distribution of therapies for the treatment of central and peripheral nervous system in Italy and internationally. The company was founded in 1998 and is headquartered in Bresso, Italy. NEWRON PHARMA operates under Biotechnology classification in Switzerland and is traded on Switzerland Exchange. It employs 24 people.
Please note, the imprecision that can be found in Newron Pharmaceuticals' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Newron Pharmaceuticals SpA. Check Newron Pharmaceuticals' Beneish M Score to see the likelihood of Newron Pharmaceuticals' management manipulating its earnings.
Newron Pharmaceuticals Workforce Analysis
Traditionally, organizations such as Newron Pharmaceuticals use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Newron Pharmaceuticals within its industry.Newron Pharmaceuticals Manpower Efficiency
Return on Newron Pharmaceuticals Manpower
| Revenue Per Employee | 230.5K | |
| Revenue Per Executive | 1.4M | |
| Net Loss Per Employee | 596K | |
| Net Loss Per Executive | 3.7M |
Additional Tools for Newron Stock Analysis
When running Newron Pharmaceuticals' price analysis, check to measure Newron Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Newron Pharmaceuticals is operating at the current time. Most of Newron Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Newron Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Newron Pharmaceuticals' price. Additionally, you may evaluate how the addition of Newron Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.